Background {#Sec1}
==========

Fabry disease, one of the most prevalent lysosomal storage disorders (LSD), is caused by mutations in the *GLA* gene which leads to partial or complete deficiency of the lysosomal enzyme *α*-galactosidase A (AGAL A, OMIM \*300644). Over 800 different mutations have been recorded in Fabry patients, including a variety of missense or nonsense point mutations, splicing mutations, deletions and insertions \[[@CR1]\]. Although the inheritance of Fabry disease is X-linked, up to 70% of heterozygote females are symptomatic, with some experiencing severe disease manifestations, similar to males \[[@CR1], [@CR2]\]. The mechanism behind this may in part be skewed X-inactivation but this is an area of debate \[[@CR3], [@CR4]\].

Reduced or absent activity of AGAL A results in accumulation of globotriaosylceramide (Gb3) and its derivatives, including globotriaosylsphingosine (lyso-Gb3), in plasma and cells throughout the body \[[@CR5]\]. Clinical features include neuropathic pain, characteristic angiokeratoma, gastrointestinal symptoms and fatigue, and ultimately renal failure, cardiomyopathy and stroke \[[@CR6]\]. Two broad clinical phenotypes are recognised (although there is likely to be a continuum); an early onset classical form exhibiting pain, angiokeratoma and sweating abnormalities preceding overt kidney and heart disease, and a later onset form with predominant manifestation in a single organ, usually the heart \[[@CR6]\].

Therapy is essentially replacement of the deficient enzyme by intravenous enzyme replacement therapy (agalsidase alfa (Shire), agalsidase beta (Genzyme Sanofi)) or oral pharmacological chaperone therapy (Migalastat (Amicus therapeutics)). Gene therapy is also in development \[[@CR7]\].

The pathophysiological link between accumulation of Gb3/Lyso-Gb3 and organ pathology, such as fibrosis, is not well understood. Substrate accumulation may lead to ischemia and cell death or initiate other downstream processes including inflammation, apoptosis or formation of reactive oxygen species \[[@CR8]\]. Glycosphingolipids (GSL) have themselves been implicated in both oncogenesis and potential cancer therapies \[[@CR9]\]. They are an integral part of the cell membrane and exhibit heterogeneous glycosylation and ceramide structures, thereby functioning as antigens, mediators of cell adhesion and modulators of signal transduction \[[@CR10]\]. Specific GSLs may be highly expressed in tumour cells and act as adhesion molecules in tumour cell metastasis and modulators of tumor growth \[[@CR10]\].

Elevated expression of Gb3 has been identified in multiple cancer types, including breast, colon, pancreatic, gastric, ovarian, testicular and lymphoma \[[@CR11]--[@CR17]\]. Furthermore, Gb3 expression correlates with the metastatic potential of human colon cancer and Gb3 enriched colon cancer cells have invasive characteristics, for which Gb3 expression is necessary and sufficient \[[@CR18]\]. Other glycosphingolipids relevant to cancer and Fabry disease include sphingosine-1-phosphate (S1P) and Lyso-Gb3, both of which promote cell proliferation and have been found at higher levels in the plasma of male patients compared to the plasma of controls \[[@CR5], [@CR19], [@CR20]\].

The incidence of cancer in patients with Gaucher disease, an LSD in which there is accumulation of the GSL glucocerebroside due to deficiency of glucocerebrosidase, has been reported \[[@CR21]--[@CR24]\]. The evidence is most persuasive of an increased risk of haematological cancer, especially multiple myeloma \[[@CR21]--[@CR25]\]. However, only a handful of case reports have been published describing cancer in individuals with Fabry disease and there has been no systematic study of the relative incidence of cancer in the context of Fabry disease compared to the general population \[[@CR26]--[@CR30]\].

In this study, we use retrospective data from hospital notes and patient questionnaires to review the incidence of cases of cancer and benign lesions within a large single centre patient cohort.

Methods {#Sec2}
=======

Patients and data collection {#Sec3}
----------------------------

Adult patients (age \> 18 years) who attended the Royal Free Hospital Lysosomal Storage Disorder Unit between 2012 and 2016 were eligible for inclusion in the study. Notes of patients who had consented to the retrospective database were reviewed. Additionally, a questionnaire regarding the incidence of cancer in patients and families was administered. The questionnaire had received ethical approval and all patients returning the questionnaire consented to do so. Two hundred sixty one patients were included; 11 patients were excluded from the analysis because data were insufficient, the patient was lost to follow-up before 2012 or no questionnaire had been returned.

Data collection included: gender, date of birth, treatment status, occurrence of cancer since birth (with year of occurrence) and occurrence of benign lesion since birth (with year of occurrence). Benign lesions included precancerous lesions (a histological lesion that, with time, has an increased risk of developing into cancer, for example cervical intraepithelial neoplasm), proliferative lesions (a benign tumour that does not have metastatic potential, such as a meningioma, but can cause complications e.g. due to its space occupying effect) and other lesions (such as a cholesteatoma, which is an abnormal collection of keratin).

Analysis of results and statistical methods {#Sec4}
-------------------------------------------

In order to compare cancer incidence in the general population and Fabry population, cancer incidence rates for both cohorts were calculated. The cancer incidence rate for a cohort is defined as \[[@CR31]\]$$\documentclass[12pt]{minimal}
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Let *P* be the cohort population, *n* ~*i*~ the number of new cases in year *i*, and *Y* the number of years in the study period. The total number of cases (*N*) during the study period is given by$$\documentclass[12pt]{minimal}
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Data on cases of cancer in the general population was acquired from publicly available cancer registration data (available from The Office for National Statistics website). Specifically, we used registrations of newly diagnosed cases of cancer in England between 1995 and 2014 inclusive as this was the most comprehensive data. Therefore, we used a 20-year study period from 1995 to 2014 as the primary analysis and so the incidence rate can be written as$$\documentclass[12pt]{minimal}
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The figure used for the population of England was the 2005 mid-year estimate taken from The Office of National Statistics data (50,606,000 individuals).

The cancer incidence rate for the Fabry cohort and general population cohort were compared as an incidence rate ratio \[[@CR31]\]$$\documentclass[12pt]{minimal}
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The standard deviation of log(*IR)* was calculated using$$\documentclass[12pt]{minimal}
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The method above excludes cancer cases pre-1995 and post-2014. In the Fabry cohort there were 2 cancer diagnoses pre-1995 and 5 cancer diagnoses post-2014. We therefore decided to also perform the calculations using a 22-year study period from 1995 to 2016. To do this we estimated cancer incidence in the general population in 2015 and 2016 as the same as in 2014.

Administrative requirements {#Sec5}
---------------------------

Ethics approval was gained from University College London (UCL) and the Integrated Research Application System (IRAS). Patient information was kept confidential and managed in accordance with trust data protection guidance (which incorporates the Data Protection Act of 1998).

Results {#Sec6}
=======

Characteristics of the study population {#Sec7}
---------------------------------------

The case notes and/or questionnaire data of 261 adult patients who attended the Royal Free Hospital Lysosomal Storage Disorder unit between 2012 and 2016 were included in the data analysis. Of these 163 (62%) were female and 98 (38%) were male. The median age was 53 years, with a lower quartile age of 41 years and an upper quartile age of 64 years. The majority of patients were Caucasian. Eighty four male patients (86%) and 80 female patients (49%) were receiving enzyme replacement therapy (ERT). All patients had a confirmed genetic diagnosis of Fabry disease.

Characteristics of the general UK population {#Sec8}
--------------------------------------------

As we will go on to compare the Fabry population to the general population, it is worth briefly describing some features of the UK population which have relevance to cancer incidence. Whilst almost all of the Fabry patients are Caucasian the UK population is more diverse, with 86% of the population identifying with a White ethnic group in the 2011 Census (Office for National Statistics). The median age of the UK population in 2014 was 40 years, with a lower quartile age of 21 years and an upper quartile age of 58 years (Office for National Statistics).

Characteristics of patients identified with cancer {#Sec9}
--------------------------------------------------

Twenty-five patients (10%) had a previous or current diagnosis of cancer (Table [1](#Tab1){ref-type="table"}). This was comprised of 17 females and 8 males. The most common cancer in females was breast cancer (7 cases) and in males was renal cell carcinoma (2 cases). Four patients were diagnosed with melanoma and 5 patients were diagnosed with urological malignancies (1 female with bladder cancer, 1 male with ureteric cancer, 1 female with renal cancer and 2 males with renal cancer). One female and 1 male were diagnosed with 2 separate malignancies; patient 9 had breast cancer and melanoma and patient 25 had renal cell carcinoma (clear cell) and prostate adenocarcinoma.Table 1Cancer cases in the Fabry cohortPatient numberGenderYear of birthYear of cancer diagnosisCancer TypeStatusERTSmokingFamily history of cancer (type)1Female19822016ColonAliveNoUnknownFather (unknown)2Female19631999MelanomaAliveYesNoMother (bowel)3Female19622007BowelAliveYesNoNo4Female19612000MelanomaAliveNoNoNo5Female19602004BreastAliveYesNoUnknown6Female19532014BreastAliveYesYesUnknown7Female19522008BreastAliveYesYesNo8Female19522005BreastAliveNoNoPaternal grandmother (unknown)9Female19471987 and 2006Melanoma, breastAliveNoUnknownNo10Female19452004BreastAliveNoNoNo11Female1939UnknownBasal cellAliveYesNoNo12Female19362001BreastAliveNoNoNo13Female19352016LungAliveYesYesNo14Female19341998LymphomaAliveNoNoMother (renal)15Female19321999ColonAliveNoNoNo16Female19272006BladderLost to follow-upNoNoMother (liver)17FemaleUnknown2000RenalUnknownUnknownUnknownUnknown18Male19822015RenalDeceasedNoUnknownUnknown19Male19561981TesticularAliveYesNoFather (eyelid)20Male19532010Basal cellAliveYesNoNo21Male19472002MelanomaAliveYesYesNo22Male19442010MesotheliomaDeceasedYesNoNo23Male19402016Left ureteric transitional cellAliveUnknownUnknownUnknown24Male19402016Chronic lymphocytic leukaemiaAliveNoEx-smokerNo25Male19302008Renal cell and prostateAliveYesNoNo

Comparison with general population cancer incidence rates {#Sec10}
---------------------------------------------------------

Using publicly available data from The Office for National Statistics the all-cancer (excluding non-melanoma skin cancer) incidence rate for the general population (using the study period 1995 to 2014) was 519 new cases per 100,000 per year. To calculate an all-cancer (excluding non-melanoma skin cancer) incidence rate for the Fabry population that was comparable to the above we had to exclude 7 individuals from the 25 with a current/past diagnosis of cancer. This included 2 patients with basal cell carcinoma (patients 11 and 20), 2 patients who had been diagnosed before 1994 (patients 9 and 19) and 5 patients who had been diagnosed after 2014 (patients 1, 13, 18 and 23 and 24). The all-cancer (excluding non-melanoma skin cancer) incidence rate of the Fabry population was 316 per 100,000 per year. The incidence rate ratio of the Fabry population compared to the general population was 0.61 (95% confidence interval 0.37 to 0.99).

The above approach has the disadvantage of excluding 7 of the 25 individuals with cancer. Therefore, we also compared cancer in the Fabry population and general population over longer study period, namely 1994 to 2016. To do this we made the assumption that cancer incidence in the general population in both 2015 and 2016 was the same as in 2014. This meant only 4 patients were excluded from the analysis. The cancer incidence rate for the general population became 531 per 100,000 per year and the cancer incidence rate in the Fabry population was 379 per 100,000 per year. The incidence rate ratio of the Fabry population compared to the general population was 0.71 (95% confidence interval 0.46 to 1.1).

As there were 5 cases of urological cancer and 4 cases of melanoma we compared the incidence rate of these specific cancers in the Fabry and general population. The incidence rate of malignant neoplasm of kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs in the general population was 32 per 100,000 per year (for both the 20-year and 22-year study period). Of the 5 cases in the Fabry cohort, 2 were excluded from the 20-year analysis as they were diagnosed after 2014 (patients 18 and 23). The incidence rate of malignant neoplasm of kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs in the Fabry population was 58 per 100,000 per year (1995 to 2014) and the incidence rate ratio of the Fabry population compared to the general population was 1.8 (95% confidence interval 0.58 to 5.6). With the 22-year study period, the incidence rate in the Fabry cohort was 88 per 100,000 per year and the incidence rate of the Fabry population compared to the general population was 2.7 (95% confidence interval 1.1 to 6.5). Given the significant effects of Fabry disease on the kidney parenchyma we also repeated the analysis for incidence rate of malignant neoplasm of the kidney, except renal pelvis. There were 3 cases of renal carcinoma in the Fabry cohort; 2 were included in the 20-year study period (as patient 18 was diagnosed in 2015) and all 3 were included in the 22-year study period. The incidence rate of malignant neoplasm of the kidney (except pelvis) in the general population was 12 per 100,000 per year (for both the 20-year and 22-year study periods). The incidence rate in the Fabry population was 38 per 100,000 per year for the 20-year study period, giving an incidence rate ratio of the Fabry population compared to the general population of 3.3 (95% confidence interval 0.83 to 13). In the 22-year study period, the incidence rate in the Fabry population was 52 per 100,000 per year, giving an incidence rate ratio of the Fabry population compared to the general population of 4.3 (95% confidence interval 1.4 to 13).

The malignant melanoma incidence rate in the general population is 16 per 100,000 per year (study period 1995 to 2014). One of the 4 melanoma cases in the Fabry cohort was excluded from the analysis as she had been diagnosed in 1987 (patient 9). The incidence rate of malignant melanoma in the Fabry population was 58 per 100,000 per year (study period 1995 to 2014). The incidence rate ratio of the Fabry population compared to the general population was 3.6 (95% confidence interval 1.2 to 11). In the Fabry cohort there were no melanoma diagnoses post 2014. When the calculations were repeated with the extended study period (1994 to 2016), the incidence rate in the general population was 17 per 100,000 per year, the incidence rate in the Fabry cohort was 53 per 100,000 per year and the incidence rate ratio was 3.1 (95% confidence interval 0.99 to 9.5).

Characteristics of patients identified with benign lesions {#Sec11}
----------------------------------------------------------

Twenty-four patients in the cohort (9%), 17 females and 7 males, had one or more diagnoses of benign lesions (Table [2](#Tab2){ref-type="table"}). The most common were growths in neurological tissues (5 cases), colon polyps (5 cases), benign breast lesions (4 cases), atypical moles (3 cases), renal lesions (2 cases) and cervical intraepithelial neoplasm (2 cases).Table 2Cases of benign lesions in the Fabry cohortPatient numberGenderYear of birthYear of benign lesion diagnosisBenign lesionStatusERTSmokingFamily history of cancer (type)26Female1986UnknownBenign acoustic neuromaAliveNoNoUnknown27Female19842004Cervical intraepithelial neoplasiaAliveYesNoMaternal grandmother (unknown)1Female1982UnknownAtypical moleAliveNoUnknown28Female19792011Small falx meningiomaLost to follow-upNoNoFather (unknown)29Female1976UnknownCervical intraepithelial neoplasiaAliveNoUnknownNo30Female19752005Fibroadenoma of breastAliveNoYesNo31Female19722007Atypical moleAliveNoNoNo32Female19691987CraniopharyngiomaAliveNoNoNo33Female19662010ProlactinomaAliveNoYesUnknown34Female19622001 and 2003Fibroadenoma of breast, lipomaAliveYesYesNo4Female19612001Atypical moleAliveNoNoNo35Female19612009Breast benign lesionAliveYesNoUnknown36Female1959UnknownColon polypLost to follow-upYesYesNo37Female19582016MeningiomaAliveYesUnknownUnknown38Female19431990, 1995 and 2011Colon polyps ×2, nodular lesion left adrenalAliveYesEx-smokerNo13Female19352001Colon polypAliveYesEx-smokerNo16Female19271972Benign breast neoplasmLost to follow-upNoNoMother (Liver)20Male19531974Left ear cholesteatomaAliveYesNoNo39Male19512006Gastric dysplasiaLost to follow-upYesNoUnknown40Male19492005Colon polypAliveYesYesUnknown41Male19392010Adrenal adenomaAliveYesEx-smokerNo42Male19352010Monoclonnal gammopathy of undetermined significance (MGUS)Lost to follow-upYesNoNo43Male19332009Neurofibroma, haemangiomaDeceasedYesEx-smokerNo44Male19312001 and 2006Colonic polypsDeceasedYesEx-smokerNo

Three patients were diagnosed with two benign lesions; patient 34 had fibroadenoma of the breast and lipoma, patient 38 had colon polyps and renal nodule and patient 43 had neurofibroma and haemangioma.

Five patients were diagnosed with both a cancer and a benign lesion; patient 1 had atypical mole and colon cancer, patient 4 had atypical mole and melanoma, patient 13 had colon polyp and lung cancer, patient 16 had benign breast neoplasm and bladder carcinoma, and patient 20 had left ear cholesteatoma followed by basal cell carcinoma.

Comparison with general population meningioma incidence rates {#Sec12}
-------------------------------------------------------------

Benign tumours and precancerous lesions in the general population are not systematically recorded in the manner of malignancies and therefore it was not possible to compare our Fabry cohort to the general population except in the case of benign neoplasm of meninges.

There were 2 diagnoses of benign neoplasm of the meninges in the Fabry cohort. For the 20-year study period (1995 to 2004) the incidence rate of benign neoplasm of meninges in the general population was 2.8 per 100,000 per year. One diagnosis of benign meningioma occurred between 1995 and 2014 and the incidence rate of benign neoplasm of meninges in the Fabry population over this period was 19 per 100,000 per year. The incidence rate ratio of the Fabry population compared to the general population was 6.8 (95% confidence interval 0.96 to 49).

For the 22-year study period (1995 to 2016) the incidence in the general population was 2.9 per 100,000 per year and the Fabry population was 35 per 100,000 per year. The incidence rate ratio was 12 (95% confidence interval 3.0 to 48).

Discussion {#Sec13}
==========

Cancer in patients with Fabry disease {#Sec14}
-------------------------------------

### All cancer (excluding non-melanoma skin cancer) incidence {#Sec15}

Our study identified 25 cases of cancer in the Fabry cohort. When compared to the general population there appeared to be a borderline-significant reduction in risk of cancer in the Fabry patients with an incidence rate ratio of 0.61 (95% confidence interval 0.37 to 0.99) in the 1995--2014 analysis and an incidence rate ratio of 0.71 (95% confidence interval 0.46 to 1.1) in the 1995--2016 analysis.

Reliable comparison of our small Fabry patient cohort to the general population is challenging due to multiple confounding factors which may explain the difference in cancer risk. The demographics of the two populations also differ with a median age of around 41 years in the general population and 53 years in the Fabry population. The Fabry population is followed up yearly in clinic and frequent interaction with health care services may lead to a healthier lifestyle and earlier risk factor intervention. For example, Fabry patients have their smoking status, weight, blood pressure, cholesterol and basic bloods monitored at each clinic visit. In addition, frequent medical reviews may help to identify precancerous lesions before they become malignant.

There may also be ascertainment bias and cases of cancer in the cohort may be missing. In this study, a high proportion of the cancer cases were recent diagnoses, suggesting recording of malignancies could have improved and older cases may be missing from the dataset. Similarly, a study of malignancy in Gaucher disease described a lower risk of solid tumours (when compared to the general population) and ascertainment bias was recognised as a potential factor \[[@CR25]\].

However, it is possible that alteration in the sphingolipid profile could impact on cancer development. Fabry disease affects endothelial cells and results in abnormal tissue perfusion; since angiogenesis is a requirement for tumour growth, neoplasia in Fabry disease may be compromised by chronic ischemia \[[@CR32]\]. In addition, a higher baseline apoptotic rate may be protective against malignant transformation \[[@CR33]\].

### Urological cancers {#Sec16}

There were 5 cases of urological cancer in the Fabry cohort. Two were excluded in the 20-year analysis and there was an incidence rate ratio of 1.8 (95% confidence interval 0.58 to 5.6). However, in the 22-year analysis all 5 cases could be included and this led to an incidence rate ratio of 2.7 (95% confidence interval 1.1 to 6.5). Considering renal cancer alone, there were 2 cases in the 20-year analysis with an incidence rate ratio of 3.3 (95% confidence interval 0.83 to 13) and 3 cases in the 22-year analysis with an incidence rate ratio of 4.3 (95% confidence interval 1.4 to 13). Therefore, this may represent an excess of urological malignancy, and also specifically renal cancers, in the Fabry cohort.

This is of particular relevance because the kidneys can be severely affected in Fabry disease, with proteinuria and end stage renal function possible if the condition is untreated \[[@CR6]\]. Chronic kidney damage and inflammation may be carcinogenic, as could exposure to excess sphingolipids.

Patients with Fabry disease have more frequent investigation compared to the general population, including blood tests, urine analysis and renal ultrasounds. This might lead to an increase in the detection of renal carcinoma, however the natural history of renal cancer would suggest that similar cases in the general population would not go undetected indefinitely \[[@CR34]\].

There is one case of testicular cancer in the Fabry cohort. This is of particular interest because azoospermia and infertility are common in 'classic' Fabry males and, should more cases of testicular cancer emerge, the mechanisms behind the defects in testicular function may merit further investigation \[[@CR35]\].

### Malignant melanoma {#Sec17}

We also detected a possible excess of melanoma in the Fabry cohort, with an incidence rate ratio of 3.6 (95% confidence interval 1.2 to 11) in the 20-year analysis and an incidence rate ratio of 3.1 (95% confidence interval 0.99 to 9.5) in the 22-year period.

Skin changes, such as angiokeratoma and telangiectasia, are common manifestations of Fabry disease and the presence of cutaneous vascular lesions is correlated with the severity of systemic manifestations \[[@CR36]\]. It is possible that abnormalities in the skin could be linked to the increased rates of melanoma in Fabry patients.

However, the majority of patients in the Fabry cohort are Caucasian (which confers a higher risk of melanoma) and the national data is likely to reflect the greater variation of ethnicities and skin types in the general population. We were also unable to collect further data regarding risk factors such as sun exposure. Skin is reviewed frequently in clinic and many patients will have formal dermatology check-ups. Higher detection rates may explain this apparent excess but, as with urological cancer, malignant melanoma inevitably tends to self-declare.

Benign lesions in patients with Fabry disease {#Sec18}
---------------------------------------------

Twenty-four patients in the Fabry cohort had a documented benign lesion. Whilst benign breast lesions, colon polyps and atypical moles are frequently seen in clinical practice, benign growths of neurological tissues were the most common benign lesion in Fabry patients (5 cases). There is a single case report of 3 Fabry patients with meningiomas \[[@CR37]\].

Benign growths of neurological tissue may be over represented in our series; given the high stroke risk in Fabry, these patients have routine brain MRI scans and thus some meningiomas could be incidental findings. However, it is possible that vascular abnormalities in Fabry disease contribute to benign brain tumour growth.

Conclusion {#Sec19}
==========

Overall our data suggests that patients with Fabry disease do not seem to be at highly increased risk of cancer development. However, there may be an increased incidence of melanoma, urological cancers and benign meningioma in Fabry patients. This could be due stimulation by lyso-lipids, disease-related inflammation and vascular abnormalities. Limitations of our study include recall bias and ascertainment bias (due to increased monitoring frequency of the population). Further studies should address these problems prospectively, in a larger cohort of patients.
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